Healthcare / Medical DistributionHKSE
$0.64
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-225.2M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
12/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$413M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-168.5%
↓Gross Margin
47.8%
↓Debt/Equity
0.53
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
-2.0%
FCF CAGR
—
FCF margin
-5.2%
FCF / Net income
0.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.62B · net income $-924.2M · FCF $-84.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $1.62B | $1.62B | $3.49B | $3.69B | $2.99B | $1.76B |
| Net Income | $-924.2M | $-924.2M | $-516.4M | $-323.1M | $-1.69B | $-4.14B |
| EBITDA | $-884.3M | $-884.3M | $-372.3M | $-208.4M | $-1.58B | $-4.15B |
| EPS | -1.52 | -1.52 | -0.89 | -0.60 | -5.62 | -7.29 |
| Gross Margin | 47.8% | 47.8% | 24.7% | 24.6% | 26.5% | 32.4% |
| Operating Margin | -17.5% | -17.5% | -6.7% | -8.6% | -18.9% | -40.3% |
| Net Margin | -56.9% | -56.9% | -14.8% | -8.8% | -56.5% | -235.6% |
| Balance Sheet | ||||||
| Debt/Equity | 0.53 | 0.53 | 0.25 | 0.15 | 0.12 | -1.27 |
| Current Ratio | 1.03 | 1.03 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-84.7M | $-84.7M | $-225.2M | $-263.5M | $-809.9M | $-755.0M |
| Returns | ||||||
| ROE | -168.5% | -168.5% | -35.5% | -17.7% | -91.3% | 58.0% |
| Valuation | ||||||
| P/B | 0.71 | 0.71 | 0.48 | 1.80 | 1.82 | — |
| Growth & Yield | ||||||
| Revenue Growth | -53.5% | -53.5% | -5.5% | 23.5% | — | — |
| EPS Growth | -70.8% | -70.8% | -48.3% | 89.3% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-38.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.89 → -1.52
Residual
-38.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.